CLINICAL TRIALS PROFILE FOR VIIBRYD
✉ Email this page to a colleague
All Clinical Trials for VIIBRYD
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01473381 ↗ | Safety and Efficacy of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2011-12-01 | The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder. |
| NCT01473394 ↗ | Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2011-12-01 | The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder. |
| NCT01573598 ↗ | Safety and Efficacy of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2012-04-01 | Safety and Efficacy of Vilazodone in Major Depressive Disorder |
| NCT01574183 ↗ | Vilazodone Treatment for Marijuana Dependence | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2012-08-01 | Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM. |
| NCT01574183 ↗ | Vilazodone Treatment for Marijuana Dependence | Completed | Medical University of South Carolina | Phase 2 | 2012-08-01 | Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency management intervention (CM)and motivational enhancement therapy (MET)will be incorporated to encourage study engagement and retention, and genomic DNA will be extracted to characterize subjects according to polymorphisms of genes potentially relevant to the activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM. |
| NCT01608295 ↗ | Vilazodone for Treatment of Geriatric Depression | Completed | Forest Laboratories | Phase 4 | 2012-07-01 | The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VIIBRYD
Condition Name
Clinical Trial Locations for VIIBRYD
Trials by Country
Clinical Trial Progress for VIIBRYD
Clinical Trial Phase
Clinical Trial Sponsors for VIIBRYD
Sponsor Name
